Pharmaron Beijing Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Pharmaron Beijing Co., Ltd. carries a market capitalization of 45.16B, placing it among publicly traded companies globally. Its enterprise value stands at 47.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 45.16B |
| Enterprise Value | 47.72B |
Share Statistics
Pharmaron Beijing Co., Ltd. currently has 1.78B shares outstanding.
| Shares Outstanding | 1.78B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Pharmaron Beijing Co., Ltd. trades at a trailing price-to-earnings ratio of 31.27. The price-to-sales ratio is 3.29, and the price-to-book ratio stands at 5.04.
| PE Ratio | 31.27 |
| PS Ratio | 3.29 |
| PB Ratio | 5.04 |
| P/TBV Ratio | 3.92 |
| P/FCF Ratio | 19.28 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Pharmaron Beijing Co., Ltd. trades at an EV/EBITDA multiple of 22.41 and an EV/FCF ratio of 19.90. The EV/Sales ratio of 3.64 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.41 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.64 |
| EV / EBITDA | 22.41 |
| EV / EBIT | 22.41 |
| EV / FCF | 19.90 |
Financial Position
Pharmaron Beijing Co., Ltd. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.90, indicating elevated leverage, while an interest coverage ratio of 10.67 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.53 |
| Quick Ratio | 0.43 |
| Debt / Equity | 40.90 |
| Debt / EBITDA | 2.86 |
| Interest Coverage | 10.67 |
Financial Efficiency
Pharmaron Beijing Co., Ltd. posts a return on equity of 16.93 and a return on invested capital of 8.04.
| Return on Equity (ROE) | 16.93 |
| Return on Assets (ROA) | 5.73 |
| Return on Invested Capital (ROIC) | 8.04 |
| Return on Capital Employed (ROCE) | 11.08 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.89 |
Taxes
Over the trailing twelve months, Pharmaron Beijing Co., Ltd. has paid 393.33M in income taxes, reflecting an effective tax rate of 23.45.
| Income Tax | 393.33M |
| Effective Tax Rate | 23.45 |
Stock Price Statistics
Pharmaron Beijing Co., Ltd.'s stock has gained approximately 27.69424% over the past 52 weeks. The 50-day moving average sits at 26.09, while the 200-day moving average is 29.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | 27.69424% |
| 50-Day Moving Average | 26.09 |
| 200-Day Moving Average | 29.19 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Pharmaron Beijing Co., Ltd. generated 13.11B in revenue and converted that into 1.38B in net income, yielding earnings per share of 0.73. EBITDA reached 2.13B, while operating income came in at 2.13B.
| Revenue | 13.11B |
| Gross Profit | 4.52B |
| Operating Income | 2.13B |
| Pretax Income | 1.68B |
| Net Income | 1.38B |
| EBITDA | 2.13B |
| EBIT | 2.13B |
| Earnings Per Share (EPS) | 0.73 |
Balance Sheet
Pharmaron Beijing Co., Ltd. holds 2.16B in cash and equivalents against 6.08B in total debt, resulting in a net debt position of 3.91B. Total book value stands at 8.57B, with working capital of 2.62B providing operational flexibility.
| Cash & Cash Equivalents | 2.16B |
| Total Debt | 6.08B |
| Net Debt | 3.91B |
| Equity (Book Value) | 8.57B |
| Book Value Per Share | 4.87 |
| Working Capital | 2.62B |
Cash Flow
After subtracting -2.24B in capital expenditures, free cash flow totaled -2.24B - equivalent to -1.28 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -2.24B |
| Free Cash Flow | -2.24B |
| FCF Per Share | -1.28 |
Margins
Pharmaron Beijing Co., Ltd. operates with a gross margin of 34.47, reflecting its pricing power and cost economics. The operating margin of 16.24 and net profit margin of 10.53 provide insight into operational efficiency.
| Gross Margin | 34.47 |
| Operating Margin | 16.24 |
| Pretax Margin | 12.79 |
| Profit Margin | 10.53 |
| EBITDA Margin | 16.24 |
Dividends & Yields
The company's payout ratio of 20.17 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.14 |
| Dividend Yield | N/A |
| Payout Ratio | 20.17 |
| Shareholder Yield | 0.57 |
| FCF Yield | 5.19 |
Stock Splits
Pharmaron Beijing Co., Ltd.'s most recent stock split took place on July 27, 2023 with a 2:3 split ratio.
| Last Split Date | 7/27/2023 |
| Split Ratio | 2:3 |
Scores
Pharmaron Beijing Co., Ltd. posts an Altman Z-Score of 4.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.05 |